Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Renke

Oral & Maxillofacial Surgery Rochester Hills, MI Doctor of Dentistry

NPI 1114935632 CMS profile 277103

1460 Walton Blvd, Ste 10, Rochester Hills, MI 48309

Open in the dashboard

General payments

$1,407

30 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Renke of Rochester Hills, MI is reported in the CMS Open Payments database as having received $1,407 across 30 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Oral & Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $124 3
2024 General $75 3
2023 General $34 2
2022 General $54 2
2021 General $74 2
2020 General $322 5
2019 General $724 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Renke
  • Oral & Maxillofacial Surgery median
  • Middle half of Oral & Maxillofacial Surgery
  • National median

In program year 2025, general payments to Paul Renke were reported at $124. Among 792 Oral & Maxillofacial Surgery profiles paid that year, the median was $184 and the middle half received between $61 and $541.

Show as a table
Year Paul Renke Oral & Maxillofacial Surgery median Middle half National median
2019 $724 $178 $56–$584 $163
2020 $322 $106 $38–$316 $114
2021 $74 $165 $57–$511 $132
2022 $54 $173 $63–$494 $149
2023 $34 $184 $62–$521 $160
2024 $75 $197 $65–$603 $164
2025 $124 $184 $61–$541 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $885 10 payments
  2. Zimvie Inc. $216 7 payments
  3. Salvin Dental Specialties, Inc. $159 6 payments
  4. Nobel Biocare USA $96 4 payments
  5. BioHorizons Implant Systems Inc. $34 2 payments
  6. Biolase, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $757 25 payments
  2. Education $650 5 payments
Products named General payments · program years 2019–2025
  1. Revitalize $500 3 payments
  2. TSX Implants $199 6 payments
  3. Diem2 $142 3 payments
  4. Dental Product Portfolio $108 1 payment
  5. NOBELACTIVE Dental implant $78 3 payments
  6. NOBELPARALLEL $78 3 payments
  7. All T3 Implants $75 1 payment
  8. BioHorizons Dental Implants $34 2 payments
  9. Eztetic $23 1 payment
  10. NOBELACTIVE Dental implant $18 1 payment
  11. Other $33 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

649

Median for Maxillofacial Surgery: 343

Drug cost

$2,071

Median for Maxillofacial Surgery: $1,437

Branded share of claims

11.2%

Median for Maxillofacial Surgery: 21.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Chlorhexidine Gluconate Generic 161 $681
Amoxicillin Generic 258 $546
Cephalexin Generic 48 $297
Ibuprofen Generic 59 $179
Clindamycin Hcl Generic 22 $139
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 43 $85
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 13 $63
Ibu Ibuprofen Brand 17 $43
Tramadol Hcl Generic 28 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 692 Part D prescribers listed as Maxillofacial Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$3,479

Medicare's payments for the services billed

Medicare patients

16

Average age 75

Services billed

16

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Oral & Maxillofacial Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record